Annals of Surgical Oncology

, Volume 18, Issue 6, pp 1624–1629 | Cite as

Medium-Sized (3.1–5.0 cm) Hepatocellular Carcinoma: Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Radiofrequency Ablation Alone

  • Jin Hyoung Kim
  • Hyung Jin Won
  • Yong Moon Shin
  • Sung Hee Kim
  • Hyun-Ki Yoon
  • Kyu-Bo Sung
  • Pyo Nyun Kim
Hepatobiliary Tumors

Abstract

Purpose

This study was designed to retrospectively compare the effectiveness of combined transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with that of RFA alone in patients with medium-sized (3.1–5.0 cm) hepatocellular carcinoma (HCC).

Methods

From March 2000 to April 2010, 57 patients, each with a single medium-sized HCC, were treated with combined TACE and RFA, and 66 were treated with RFA alone.

Results

During follow-up (mean, 42.5 ± 33.2 months; range, 2.6–126.2 months), local tumor progression was observed in 40% of treated lesions in the combined treatment group and in 70% in the RFA-alone group. The 1-, 3-, 5-, and 7-year local tumor progression rates were significantly lower in the TACE + RFA group (9%, 40%, 55%, and 66%, respectively) than in the RFA-alone group (45%, 76%, 86%, and 89%, respectively; P < 0.001). Multivariate analysis showed that treatment allocation (odds ratio [OR], 1.78; P = 0.016) and Child-Pugh class (OR, 1.96; P = 0.008) were significant independent factors associated with patient survival. The rates of major complications were 0% for the combined treatment group and 3% for the RFA-alone group.

Conclusions

The combination of TACE and RFA is safe and provides better local tumor control than RFA alone for the treatment of patients with medium-sized HCC. Our multivariate analysis showed that RFA-alone treatment and Child-Pugh class B were poor independent factors for determining the patient survival period.

Notes

Conflicts of interest

The authors have no conflicts of interest and nothing to disclose.

References

  1. 1.
    Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg. 2000;232:381–91.PubMedCrossRefGoogle Scholar
  2. 2.
    Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Shibata T, Shibata T, Maetani Y, Isoda H, Hiraoka M. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. Radiology. 2006;238:346–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology. 2000;214:761–8.PubMedGoogle Scholar
  6. 6.
    Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma. Cancer. 2009;115:1914–23.PubMedCrossRefGoogle Scholar
  7. 7.
    Xu HX, Lu MD, Xie XY, et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol. 2005;60:1018–25.PubMedCrossRefGoogle Scholar
  8. 8.
    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(Suppl 1):S20-S37.PubMedCrossRefGoogle Scholar
  9. 9.
    Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119–26.PubMedGoogle Scholar
  10. 10.
    Kang SG, Yoon CJ, Jeong SH, et al. Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study. J Vasc Interv Radiol. 2009;20:1570–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamakado K, Nakatsuka A, Ohmori S, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol. 2002;13:1225–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Takaki H, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinoma 5 cm or smaller: risk factors for local tumor progression. J Vasc Interv Radiol. 2007;18:856–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Lau H, Fan ST, Ng IO, Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer. 1998;83:2302–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference European Association for the Study of the liver. J Hepatol. 2001;35:421–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology. 2010;255:270–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2009;20:S377–90.PubMedCrossRefGoogle Scholar
  17. 17.
    Dodd GD, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics. 2000;20:9–27.PubMedGoogle Scholar
  18. 18.
    Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009;252:905–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology. 1994;106:1618–24.PubMedGoogle Scholar
  20. 20.
    Khan MR, Poon RTP, Ng KK, et al. Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. Arch Surg. 2007;142:1136–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Maluccio M, Covey AM, Gandhi R, et al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J Vasc Interv Radiol. 2005;16:955–61.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Jin Hyoung Kim
    • 1
    • 2
  • Hyung Jin Won
    • 1
    • 2
  • Yong Moon Shin
    • 1
    • 2
  • Sung Hee Kim
    • 1
    • 2
  • Hyun-Ki Yoon
    • 1
    • 2
  • Kyu-Bo Sung
    • 1
    • 2
  • Pyo Nyun Kim
    • 1
    • 2
  1. 1.Department of RadiologyAsan Medical Center, University of Ulsan College of MedicineSeoulRepublic of Korea
  2. 2.Research Institute of RadiologyAsan Medical Center, University of Ulsan College of MedicineSeoulRepublic of Korea

Personalised recommendations